Kazia Therapeutics Limited - KZIA STOCK NEWS

Kazia Therapeutics (KZIA) presents new data on pipeline molecules at AACR, showing promising results for EVT801 and paxalisib in cancer treatment. The data includes phase 1 study results and combination therapy efficacy for atypical teratoid/rhabdoid tumors.

Kazia Therapeutics Limited announces positive results from a Phase I trial combining paxalisib with radiation therapy for treating patients with PI3K pathway mutation brain metastases. The study shows promising safety and clinical activity, with the primary endpoint achieved.

Kazia Therapeutics (KZIA) appoints pharma industry executive Robert Apple as Non-Executive Director and Bryce Carmine as Chairman. Mr. Apple brings over 25 years of leadership experience, including roles at Antares Pharma and InKine Pharmaceutical. Mr. Carmine has a distinguished career at Eli Lilly & Co. CEO Dr. John Friend expressed delight with the appointments, emphasizing the value of their expertise for the company's growth.

Kazia Therapeutics Limited (NASDAQ: KZIA) closed a purchase and sale of up to 4,444,445 of the Company's American Depositary Shares (ADSs) at a purchase price of $0.45 per ADS, raising approximately $2 million in gross proceeds. The Company also issued unregistered warrants to purchase up to 4,444,445 ADSs at an exercise price of $0.583 per ADS, with H.C. Wainwright & Co. acting as the exclusive placement agent.

Kazia Therapeutics Limited (NASDAQ: KZIA) announced a registered direct offering and a concurrent private placement for the purchase and sale of up to 4,444,445 of the Company's American Depositary Shares at a purchase price of $0.45 per ADS, along with unregistered warrants to purchase up to 4,444,445 ADSs with an exercise price of $0.583 per ADS.

Kazia Therapeutics Limited (NASDAQ: KZIA) has signed a non-binding Letter of Intent with an undisclosed biotechnology company for the license of worldwide rights, other than mainland China, Hong Kong, Macao, and Taiwan, to develop and commercialize a pharmaceutical product containing paxalisib in an indication outside of cancer. The proposed terms include an upfront payment, potential clinical and regulatory milestone payments, as well as commercial sales-based royalties and milestones. The companies are currently negotiating the definitive license agreement.

Kazia Therapeutics Limited (KZIA) provided key highlights of the clinical and preclinical paxalisib related presentations at the Society of Neuro-Oncology 2023 Annual Meeting. The preliminary overall survival data from the PNOC022 clinical study is encouraging, showing potential as an alternative to current standard therapies. Notable findings from the presentations include the combination of ONC201 and paxalisib in treating diffuse midline glioma, exploiting the genetic dependency on PI3K/mTOR signaling for the treatment of H3-altered Diffuse Midline Glioma, and the Phase I study of paxalisib and radiotherapy for CNS disease harboring PI3K pathway mutations. The company has expanded the study after identifying the maximal tolerated dose and observed signals of clinical activity, and they are also exploring the use of plasma circulating tumor DNA as a biomarker to assess patient treatment response. The PNOC022 trial, using an adaptive platform design for patients with diffuse midline gliomas, has enrolled 137 patients across three cohorts with preliminary analyses showing promising median overall survival and progression-free survival rates.

Kazia Therapeutics Limited (NASDAQ: KZIA) received a deficiency notification from Nasdaq, stating non-compliance with the minimum bid price requirement. The company has 180 days to regain compliance, during which its securities will continue to trade as normal on Nasdaq-CM under the ticker KZIA.

Kazia Therapeutics Limited (NASDAQ: KZIA) announces positive preliminary results from a combination therapy trial for diffuse midline gliomas (DMGs) at the Society of Neuro-Oncology 2023 Annual Meeting. The trial, PNOC022, has shown a median overall survival (OS) of 16.5 months, significantly higher than the standard of care. The study has enrolled 68 patients and has partnered with 29 leading children's cancer centers globally.